Industry News

Walmart Testing Text-to-Shop Tool

Walmart is continuing to look for new ways to enhance how consumers shop for their day-to-day necessities.

In order to meet that goal, the retailer recently announced that it will work with Global Tech and Store No. 8 on testing a text-to-shop tool in select areas.

The new collaboration, which was disclosed on Walmart’s website, is identifying how consumers shop and how their preferences are constantly changing, the companies said.

“We’re learning a lot about when and how customers prefer a conversational experience, and we look forward to making this more widely available in the future,” Dominique Essig, vice president of conversational commerce at Store No. 8, said. “Walmart gets it, and we’re here to make the shopping process simple and convenient. This type of innovative customer experience is exactly what we build every day. And while Walmart has offered voice shopping for years, text shopping is just getting warmed up.”

Essig also noted that in addition to helping busy families, a key benefit of this new service is that it’s personalized. “By understanding our customers’ preferences, we also solve the paradox of choice and save them time by serving up what we know they love best. Most importantly, we offer Walmart customers the opportunity to shop no matter where they are, and to communicate naturally by simply asking for what they want, any way they want,” he said.

St. Ives’ Solutions Looks To Reduce Skin Care Stress

St. Ives is aiming to help ease any stress that Gen Z members might face when it comes to choosing the right skin care product by launching its new Solutions line.

Solutions features acnecontrol products to help fight breakouts and clear skin products to help care for post-acne skin.

The collection includes the following: • Solutions Acne Control Cleanser, made with salicylic acid and natural tea tree extract, works to clear blemishes and prevent new blackheads and whiteheads from forming; • Solutions Acne Control Spot Treatment features natural tea tree extract and 2% salicylic acid. The spot treatment aims to reduce pimple size, swelling and redness. • Solutions Clear Skin SPF Moisturizer, a lightweight gel cream made with natural tea tree extract. It contains SPF 25 to protect skin and has a sheer appearance that works on all skin tones; and • Solutions Clear Skin Toner, a 3-in-1 solution that contains witch hazel, natural tea tree extract and vitamin B3 to brighten skin; fade dark spots; and remove dirt, oil and makeup while reducing the appearance of pores.

To celebrate the launch of this new collection, the brand is working on a campaign with actress and college student Sierra Capri that calls on students to share good, clean and fun ways to de-stress for a chance to win up to $50,000 in free tuition and books for one year.

“We know the cost of college is an issue that can weigh on the minds of Gen Z,” said Dawn Hedgepeth, vice president of skin care at Unilever. “At St. Ives, we believe in infusing fun into one’s daily routine to find ways to de-stress. We hope our new Solutions range — a collection of effective and affordable products — will help reduce the stress of skin care, especially when it comes to breakouts. We’re also excited to offer one lucky student the opportunity to win funds for free tuition and books to help alleviate some of that financial stress.”

To enter, undergrad students can tag @stivesskin and use the hashtags #StIvesScholarship and #Contest on a post with an original version of Capri’s video, which was shared on Instagram.

“As a full-time student studying biology, who was also juggling acting auditions, I remember the financial stress of college like it was yesterday,” Capri said. “Many times, that stress would manifest as breakouts. I wish at the time I had a line like St. Ives Solutions — it’s an easy, low-stress approach to caring for skin and keeping it in glowing condition.”

Cipla launches the fi rst AB-rated generic to Durezol

®1

(Difl uprednate Ophthalmic Emulsion 0.05%)

Indication & Usage2:

Ocular Surgery: Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. Endogenous Anterior Uveitis: Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis.

Product Name: Brand Reference: Strength: ND: Size: Dosage Form: TE Code: Case Size: Difluprednate Ophthalmic Emulsion2 DUREZOL®

0.05% 69097-341-35 5mL Ophthalmic Emulsion AB 72

NOW AVAILABLE AT ALL MAJOR WHOLESALERS/DISTRIBUTORS. To place your order contact them today.

› Contact CIPLA:

Non-Medical Inquiries:

Phone: 844-CIPLA US (844-247-5287) E-mail: Ciplacs@ups.com Medical Inquiries & Reporting:

Phone: 1-866-604-3268 E-mail: DrugSafety@cipla.com Wholesaler/Distributor Order Entry Number Amerisource Bergen Cardinal McKesson 10261426 5745443 2324580

IMPORTANT SAFETY INFORMATION Contraindications: Contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures. Warnings and Precautions include: IOP Increase: May result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Cataracts: May result in posterior subcapsular cataract formation. Delayed Healing: May delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. Bacterial Infections: May suppress the host response, increasing the hazard of secondary ocular infections. Viral Infections: Patients with a history of herpes simplex requires great caution as corticosteroid medication may prolong the course in and may exacerbate the severity of many viral infections of the eye. Fungal Infections: Fungal infections of the cornea are particularly prone to develop. Topical Ophthalmic Use Only: Difluprednate ophthalmic emulsion is not indicated for intraocular administration. Contact Lens Wear: Difluprednate ophthalmic emulsion should not be instilled while wearing contact lenses. ADVERSE REACTIONS • Ocular Surgery: 5-15% of subjects included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis; 1-5% included reduced visual acuity, punctate keratitis, eye inflammation, and iritis; < 1% included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macula edema, sclera hyperemia, and uveitis. • Endogenous Anterior Uveitis: 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia punctate keratitis, and uveitis; 2-5% included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity. Pregnancy: Teratogenic Effects Pregnancy Category C. Difluprednate ophthalmic emulsion should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Nursing Mothers: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when difluprednate ophthalmic emulsion is administered to a nursing woman.

You may report side effects to the FDA at 1·800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Cipla USA, Inc. at 1-866-604-3268.

INDICATIONS & USAGE

Ocular Surgery: Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. Endogenous Anterior Uveitis: Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis. Contraindications: The use of difluprednate ophthalmic emulsion, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

WARNINGS AND PRECAUTIONS

• IOP Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored. • Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation. • Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. • Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

• Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. • Topical Ophthalmic Use Only: Difluprednate ophthalmic emulsion is not indicated for intraocular administration. • Contact Lens Wear: Difluprednate ophthalmic emulsion should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of difluprednate ophthalmic emulsion. The preservative in difluprednate ophthalmic emulsion may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of difluprednate ophthalmic emulsion.

ADVERSE REACTIONS

• Ocular Surgery: Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with difluprednate included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis. Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macula edema, sclera hyperemia, and uveitis. Most of these reactions may have been the consequence of the surgical procedure. • Endogenous Anterior Uveitis: The most common adverse reactions of those exposed to difluprednate occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis. Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.

USE IN SPECIFIC POPULATIONS

Pregnancy: Teratogenic Effects Pregnancy Category C. Difluprednate has been shown to be embryotoxic (decrease in embryonic body weight and a delay in embryonic ossification) and teratogenic (cleft palate and skeletal anomalies) when administered subcutaneously to rabbits during organogenesis at a dose of 1-10 mcg/kg/day. It is difficult to extrapolate the doses of difluprednate to maximum daily human doses of difluprednate, since difluprednate is administered topically with minimal systemic absorption, and difluprednate blood levels were not measured in the reproductive animal studies. However, since use of difluprednate during human pregnancy has not been evaluated and cannot rule out the possibility of harm, difluprednate ophthalmic emulsion should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Nursing Mothers: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when difluprednate ophthalmic emulsion is administered to a nursing woman. Pediatric Use: Difluprednate was evaluated in a 3-month, multicenter, double-masked trial in 79 pediatric patients (39 difluprednate; 40 prednisolone acetate) 0 to 3 years of age for the treatment of inflammation following cataract surgery. A similar safety profile was observed in pediatric patients comparing difluprednate to prednisolone acetate ophthalmic suspension, 1%. Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients This is a brief summary of information about Difluprednate ophthalmic emulsion. This information is not comprehensive. Visit https://www.ciplausa.com/sites/default/files/PI-Difluprednate-Ophtalmic-Emulsion.pdf or call 1-866-604-3268 to obtain the full Prescribing Information.

FDA OKs New Indication for Roche’s Tecentriq

The Food and Drug Administration has given the greenlight for Roche’s Tecentriq, or atezolizumab, as adjuvant treatment, following surgery and platinumbased chemotherapy, for adults with stage II-IIIA non-small cell lung cancer whose tumors express PDL1≥1%, as determined by an FDA-approved test.

“Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity to receive immunotherapy to increase their chances for cure,” said Levi Garraway, Roche’s chief medical officer and head of global product development.

“Today’s landmark approval gives physicians and patients a new way to treat early lung cancer that has the potential to significantly reduce risk of cancer recurrence, after more than a decade with limited treatment advances in this setting,” Garraway said.

“Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse,” said Bonnie Addario, co-founder and chair of GO2 Foundation for Lung Cancer. “With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.”

Tecentriq previously has shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications.

Additionally, Roche’s Tecentriq was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer in combination with carboplatin and etoposide, or chemotherapy.

Tecentriq also possesses four approved indications in advanced NSCLC — as either a single agent or in combination with targeted therapies and/or chemotherapies.

Tecentriq is available in three-dosing options, providing the flexibility to choose administration every two, three or four weeks.

Nestlé Rallies Nut Butter Bombs Transform Indulgent Snacking

Nestlé is looking to give consumers a wider range of options when it comes to choosing a sweet and indulgent snack by introducing its Rallies Nut Butter Bombs.

Made with nut butter and premium chocolate, these chilled snacks are made without the use of artificial colors, flavors or preservatives, the Arlington, Va.-based company said.

Available flavors include: • Brownie Almond Butter, filled with dark chocolate, almond butter and almond pieces, has a shell made of milk chocolate; • Salted Cashew Butter is covered in a dark chocolate coating; and • Raspberry Peanut Butter hits shelves in 2022 and features a dark chocolate coating wrapped around a peanut butter center that’s dotted with raspberry pieces.

“Between family, work and the stress of their daily lives, consumers are struggling to find opportunities and ways to prioritize themselves throughout the day. Seventy-four percent of consumers say “treating oneself” is the main driver of comfort snacking to combat slumps in their busy lifestyles, said Michael Darman, innovation manager at Nestlé USA.

“Eventually, we all need a ‘pick me up.’ “Nestlé Rallies offers a delicious treat with less added sugar than consumers are used to finding in similar snacks. The indulgence is a grab-and-go option and a fresh, elevated take on a traditional treat. From the initial bite into the chilled chocolate shell to the rich, smooth textures of the nut butter filling, we’re providing a treat that combines delicious ingredients to help consumers take on their day.”

Consumers can find Nestlé Rallies Nut Butter Bombs in the refrigerated aisle of select Hy-Vee stores and online at NestleRallies.com. A package of three individual bombs retails for $2.49 and a package of six retails for $19.99.